首页> 外文期刊>Modern Pathology >Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma
【24h】

Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma

机译:生色原位杂交在非小细胞肺癌中检测EGFR拷贝数扩增的验证

获取原文
           

摘要

Epidermal growth factor receptor (EGFR) gene copy number correlates with response to tyrosine kinase inhibitors in patients with nonsmall cell lung carcinoma. Fluorescence in situ hybridization (FISH), a standard methodology to detect EGFR copy number abnormalities in nonsmall cell lung carcinoma, is limited by instrumentation and cost. Chromogenic in situ hybridization (CISH) is an emerging alternative detection technique using light microscopy, but its utility in assessing EGFR copy number in lung cancer is not established. To address the utility of CISH, we studied paraffin-embedded nonsmall cell lung carcinoma specimens from 77 Taiwanese nonsmoking women treated by surgery alone. We recorded the number of signals per tumor cell nucleus, correlated EGFR copy number by CISH with FISH results, and used receiver operating characteristics to identify cut-off points for the CISH results. Tumors were classified as adenocarcinoma (n=28), mixed adenocarcinoma with bronchioloalveolar features (n=25), bronchioloalveolar carcinoma (n=2), squamous cell carcinoma (n=15), and adenosquamous carcinoma (n=7). By FISH, 29% of cases had no amplification, 18% had low polysomy, 35% had high polysomy, and 12% had gene amplification. EGFR copy number detected by CISH highly correlated with FISH (Spearman r=0.81, PEGFR CISH cut-off points that discriminate between no amplification and low polysomy (2.8 signals, P=0.09); no amplification plus low polysomy and high polysomy plus gene amplification (4.5 signals, PP=0.0003). CISH is an alternative assay to FISH in determining EGFR copy number status that may contribute to stratification of patients with nonsmall cell lung carcinoma for clinical trials and identify a subset of patients that should be treated with tyrosine kinase inhibitors.
机译:表皮生长因子受体(EGFR)基因拷贝数与非小细胞肺癌患者对酪氨酸激酶抑制剂的反应有关。荧光原位杂交(FISH)是检测非小细胞肺癌中EGFR拷贝数异常的一种标准方法,受仪器和成本的限制。生色原位杂交(CISH)是一种新兴的使用光学显微镜的替代检测技术,但尚未确定其在评估肺癌中EGFR拷贝数方面的效用。为了解决CISH的实用性,我们研究了来自77名仅接受手术治疗的台湾非吸烟女性的石蜡包埋的非小细胞肺癌标本。我们记录了每个肿瘤细胞核的信号数,通过CISH将EGFR拷贝数与FISH结果相关联,并使用了受体工作特征来确定CISH结果的临界点。肿瘤分为腺癌(n = 28),具有支气管肺泡特征的混合腺癌(n = 25),支气管肺泡癌(n = 2),鳞状细胞癌(n = 15)和腺鳞癌(n = 7)。通过FISH,29%的病例未扩增,18%的多核症低,35%的多核症高,12%的基因扩增。 CISH检测到的EGFR拷贝数与FISH高度相关(Spearman r = 0.81,PEGFR CISH临界点可区分无扩增和低多体性(2.8信号,P = 0.09);无扩增+低多体性和高多核性+基因扩增(4.5信号,PP = 0.0003)。CISH是FISH的另一种测定方法,可用于确定EGFR拷贝数状态,这可能有助于非小细胞肺癌患者的分层,以进行临床试验并确定应用酪氨酸激酶治疗的部分患者抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号